Financial Data and Key Metrics Changes - The company reported Q1 sales of $617 million, with core sales increasing by 20 basis points year over year despite a negative impact of approximately 140 basis points from currency exchange rates [12][14] - Adjusted EBITDA margin was 12.8%, down 120 basis points from the previous year, primarily due to foreign exchange impacts [14][20] - Adjusted EPS for the quarter was $0.24, slightly above expectations but down $0.02 compared to the same quarter last year [14][23] Business Line Data and Key Metrics Changes - Specialty Products and Technologies segment saw a decline of 70 basis points in core revenue year over year, while Equipment and Consumables segment increased by 170 basis points [20][22] - Consumables showed strong growth across most categories and geographies, particularly in North America [12][13] - The orthodontics business experienced growth in Spark and Brackets and Wires outside of China, while the premium implants segment continued to grow [21][22] Market Data and Key Metrics Changes - The global dental market remained stable in Q1, with underlying demand similar to the second half of 2024 [9][35] - Positive growth was noted in North America, Japan, and emerging markets, while Europe remained flat [27] - Consumer confidence indices in the U.S. have deteriorated, but this has not yet impacted the company's Q1 results [10][35] Company Strategy and Development Direction - The company is focused on a value creation plan that includes growth in consumables, Nobel, and orthodontics, as well as price capture across its portfolio [25][26] - A tariff task force has been established to manage the impact of tariffs and optimize supply chain flexibility [31][32] - The company maintains its 2025 guidance of 1% to 3% core growth and adjusted EBITDA margins of approximately 14% [11][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the dental market's long-term stability despite current macroeconomic uncertainties [27][35] - The company is navigating geopolitical uncertainties and has implemented cost controls to enhance operational productivity [10][11] - Future performance is expected to benefit from the unwinding of revenue deferrals in the second half of the year [17][19] Other Important Information - The company has made progress on its $250 million share repurchase program, purchasing $19 million worth of stock in Q1 [23] - Free cash flow was an outflow of $5 million in Q1, typical for the first quarter due to timing of incentive compensation [15][22] Q&A Session Summary Question: Current tariff exposure and mitigation strategies - The company has significant tariff exposure from U.S. goods imported into China and vice versa, with ongoing efforts to shift supply chains to mitigate impacts [42][43] Question: April trends and volume-based dynamics - April has started positively, with no major shifts in procedure types observed, indicating stability in the market [50][51] Question: Gross and net impacts from tariffs - The guidance includes current tariff activity, with confidence in mitigating impacts through various strategies [56][58] Question: Expectations for VBP in China - The ortho VBP process is progressing as expected, with anticipated benefits in the second half of the year [67][69] Question: Performance of premium and challenger implants - Challenger experienced a dip in Q1 due to fewer billing days, but no change in trajectory is expected for the year [92][94] Question: Spark average selling price trends - No major change in Spark ASP was noted, with consistent pricing and value capture expected [100][101] Question: Size of the China business and inventory management - The China business represents a high single-digit percentage of total revenue, with inventory held in China and ongoing shipments incurring tariffs [105][106]

Financial Data and Key Metrics Changes - The company reported Q1 sales of $617 million, with core sales increasing by 20 basis points year over year despite a negative impact of approximately 140 basis points from currency exchange rates [12][14] - Adjusted EBITDA margin was around 12.8%, down 120 basis points from the previous year, primarily due to foreign exchange impacts [14][19] - Adjusted EPS for the quarter was $0.24, slightly above expectations but down $0.02 compared to the same quarter last year [14][22] Business Line Data and Key Metrics Changes - Specialty Products and Technologies segment saw a core revenue decline of 70 basis points year over year, while Equipment and Consumables segment increased by 170 basis points [19][21] - Consumables showed strong growth across most categories and geographies, particularly in North America [12][13] - The orthodontics business experienced growth in Spark and Brackets and Wires outside of China, despite challenges in the Chinese market [20][25] Market Data and Key Metrics Changes - The global dental market remained stable in Q1, with underlying demand similar to the second half of 2024 [9][35] - Positive growth was noted in North America, Japan, and emerging markets, while Europe remained flat [26] - Consumer confidence indices in the U.S. have deteriorated, but this has not yet impacted the company's Q1 results [10][35] Company Strategy and Development Direction - The company is focused on a value creation plan that includes growth in consumables, Nobel, and orthodontics, as well as price capture across its portfolio [25][26] - A tariff task force has been established to manage the impacts of tariffs and optimize supply chain flexibility [31][32] - The company maintains its 2025 guidance of 1% to 3% core growth and adjusted EBITDA margins of approximately 14% [11][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the dental market's long-term stability despite current macroeconomic uncertainties [27][35] - The company is navigating challenges through cost controls and operational improvements, with a focus on maintaining strong customer service levels [10][27] - Future performance is expected to benefit from the unwinding of revenue deferrals in the second half of the year [16][87] Other Important Information - The company has made progress on its $250 million share repurchase program, purchasing $19 million worth of stock in Q1 [22] - Free cash flow was an outflow of $5 million in Q1, typical for the first quarter due to timing of incentive compensation [15][21] Q&A Session Summary Question: Current tariff exposure and mitigation strategies - The company detailed its tariff exposure primarily in U.S. goods imported into China and vice versa, with ongoing efforts to shift supply chains to mitigate impacts [41][42][43] Question: April trends and volume-based dynamics - Management noted that April has started positively, with no significant shifts in procedure types observed [49][50][51] Question: Gross and net impacts from tariffs - The guidance includes current tariff activity, with confidence in mitigating impacts but acknowledging wider error bars compared to previous guidance [56][57][58] Question: Expectations for implants and product launches - The Challenger segment experienced a decline due to fewer billing days, but no change in trajectory is anticipated for the year [91][93][95] Question: Spark average selling price trends - No major change in Spark ASP was reported, with consistent pricing and value capture noted [100][101] Question: Size of the China business and inventory management - The China business represents a high single-digit percentage of total revenue, with inventory held in China and ongoing shipments incurring tariffs [105][106][107]

Financial Data and Key Metrics Changes - First quarter revenues declined by 1% to $143 million compared to the same period in 2024, with adjusted EBITDA of $23 million, down from $24 million year-over-year [27][30][8] - Net loss for the first quarter was $1 million, an improvement from a net loss of $5 million in the first quarter of 2024 [30] - Adjusted net income increased to $7 million or $0.05 per diluted share, compared to $5 million or $0.04 per diluted share in the same period last year [30] Business Line Data and Key Metrics Changes - Grill sales increased by 13% year-over-year, benefiting from the launch of the new Woodridge series [17][20] - Consumables revenues decreased by 6% to $30 million, largely in line with expectations [27] - Accessories revenue fell by 27% to $26 million, primarily due to challenges faced by the Meter product line [27][24] Market Data and Key Metrics Changes - North American revenues rose by 6%, while revenues from the rest of the world dropped by 47%, significantly impacted by Meter's performance [28] - The first quarter typically experiences slower sales in the outdoor cooking industry, but sell-through for grills remained positive compared to the previous year [18] Company Strategy and Development Direction - The company is focused on mitigating tariff impacts through cost reductions, sourcing diversification, and strategic pricing increases [11][12][13] - Plans to reduce production in China significantly by 2026 while enhancing relationships with manufacturing partners [13] - The company has suspended forward guidance for fiscal 2025 due to uncertainties in the macroeconomic environment and consumer demand [16][34] Management's Comments on Operating Environment and Future Outlook - Management highlighted the challenges posed by tariffs and declining consumer sentiment, emphasizing the need for strategic navigation through the current macroeconomic landscape [9][10] - The company remains optimistic about its ability to offset tariff impacts and is committed to long-term growth strategies despite short-term challenges [26][36] Other Important Information - The Woodridge series received strong consumer reception, achieving an average rating of 4.8 stars, marking the highest rating for a product launch in the company's history [21] - The company is actively managing inventory levels and has reduced purchase orders to avoid overstocking amid uncertain demand [35][55] Q&A Session Summary Question: Can you provide some color around strategic price increases across your product portfolio? - Management indicated that pricing decisions were made based on historical sell-through data and product elasticity, with a focus on premium positioning and innovation [38][39] Question: Can you talk about the Meter segment and capital allocation going forward? - Management acknowledged short-term challenges in the Meter segment but emphasized a long-term strategy focused on wholesale channels and operational efficiency [44][46] Question: Have you sensed a shift in retailer willingness to take on inventory? - Management noted no significant reluctance from retailers to take inventory, but there has been a shift towards domestic fulfillment due to tariff implications [50][52] Question: Can you clarify the tariff situation regarding products from China? - Management confirmed that grills from China are subject to a total tariff of 45%, while accessories vary based on sourcing [58][60] Question: What is the approach to marketing this year? - The company is focusing on sales activation activities and in-store marketing, while top-of-funnel marketing has been deprioritized due to the uncertain environment [89][90]

Financial Data and Key Metrics Changes - First quarter revenues declined by 1% to $143 million compared to the same period in 2024, with adjusted EBITDA of $23 million, down from $24 million year-over-year [6][24][27] - Net loss for the first quarter was $1 million, an improvement from a net loss of $5 million in the first quarter of 2024 [27] - Adjusted net income increased to $7 million or $0.05 per diluted share, compared to $5 million or $0.04 per diluted share in the same period last year [27] Business Line Data and Key Metrics Changes - Grill sales increased by 13% year-over-year, benefiting from the launch of the new Woodridge series [15][24] - Consumables revenues decreased by 6% to $30 million, in line with expectations, due to a reduction in wood pellet and soup consumables [21][24] - Accessories revenue fell by 27% to $26 million, primarily due to challenges faced by Meter in the smart thermometer category [22][24] Market Data and Key Metrics Changes - North American revenues rose by 6%, while revenues from the rest of the world dropped by 47%, largely due to Meter's performance [25] - The first quarter typically experiences slower sales in the outdoor cooking industry, but sell-through for grills remained healthy into the second quarter [16][24] Company Strategy and Development Direction - The company is focused on mitigating tariff impacts through cost reductions, sourcing diversification, and strategic pricing increases [10][12][14] - Plans to reduce production in China significantly by 2026 while enhancing relationships with manufacturing partners [11][12] - The company has suspended forward guidance for fiscal 2025 due to uncertainties in the macroeconomic environment and consumer demand [14][31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by tariffs and declining consumer sentiment, emphasizing the importance of navigating the current macroeconomic climate [7][8] - The company is optimistic about its ability to offset tariff impacts through various mitigation strategies, although consumer demand remains a significant unknown [10][29] - Management expressed confidence in the long-term value of the Meter brand despite short-term pressures [42][44] Other Important Information - The Woodridge series received strong consumer reception, achieving an average rating of 4.8 stars across various platforms [19][20] - The company is actively managing inventory levels and has reduced purchase orders to avoid overstocking amid uncertain demand [32][53] Q&A Session Summary Question: Can you provide insights on strategic price increases across your product portfolio? - Management indicated that pricing decisions were made based on historical sell-through data and product elasticity, with a focus on premium positioning [35][36] Question: How is the Meter segment performing and what are the capital allocation plans? - Management acknowledged short-term challenges for Meter but emphasized a long-term strategy focused on wholesale channels and cost structure optimization [42][43] Question: Has there been a shift in retailer willingness to take on inventory? - Management noted no significant reluctance from retailers but mentioned a shift towards domestic fulfillment due to tariff implications [48][49] Question: Can you clarify the tariff situation for products sourced from China? - Management confirmed that grills from China are subject to a total tariff of 45%, while accessories vary based on sourcing [57][64] Question: What is the current status of the Walmart pellet rollout? - Management expressed excitement about the partnership with Walmart, noting it meets consumer demand for convenience [68][69]

TRAEGER INVESTOR PRESENTATION. FIRST QUARTER 2025 SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of l995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our mitigation efforts to offset the direct impact of tariffs, our implementation of strategic actions to stabiliz ...

Financial Performance - Value-added (VA) sales reached $259.3 million, a 1% increase year-over-year[9] - Adjusted EBITDA was $48.7 million, representing 18.8% of VA sales, an 8% increase year-over-year[9] - Adjusted EPS increased by 18% year-over-year to $1.13[9] - The company saw a $35 million year-over-year improvement in free cash flow due to reduced working capital[9] Segment Performance - Performance Materials segment value-added sales were $160.0 million, up 3% year-over-year, with adjusted EBITDA of $40.9 million, up 15% year-over-year[38][39] - Electronic Materials segment value-added sales were $77.8 million, with adjusted EBITDA of $13.3 million[42][43][44] - Precision Optics segment value-added sales were $21.5 million, with an adjusted EBITDA loss of $0.1 million[46][47][48] Market Performance - Semiconductor market VA sales increased by 7% to $68.3 million due to improving demand in data storage and advanced logic & memory applications[14] - Energy market VA sales increased significantly by 47% to $19.6 million, driven by a large nuclear energy shipment[14] - Consumer Electronics market VA sales decreased by 17% to $46.6 million due to general market uncertainty[14] Financial Outlook - The company expects Q2 to be slightly better than Q1[23] - The company anticipates a $0.10 to $0.15 impact from China tariffs in Q2 and a potential $0.40 to $0.50 impact in the second half of the year[23] - The company expects to deliver a 20%+ adjusted EBITDA margin for the full year[23]

Financial Data and Key Metrics Changes - The company expects EPS to decline about 30% for the first half of the year, with Q2 expected to be down less than Q1, which was down over 30% [12][13][14] - Gross margin for Q2 is expected to decrease by approximately 700 basis points, influenced by tariff components and increased SG&A expenses [14][13] Business Line Data and Key Metrics Changes - The company reported a 10% increase in its business, with a 100 basis point increase in market share, particularly in the sweets category [23] - The company anticipates low single-digit growth in everyday chocolate for the second half of the year, driven by strong innovation [35] Market Data and Key Metrics Changes - The company has seen strong growth in international markets, particularly in Brazil, where organic sales grew double digits [98] - The competitive environment in international markets has normalized, aiding the company's performance [98] Company Strategy and Development Direction - The company is focused on mitigating tariff impacts through various strategies, including lobbying and operational adjustments [10][9] - The company aims to continue growing its chocolate business while expanding into the salty snacks and sweets categories, targeting younger and more diverse demographics [79][78] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a path to earnings growth next year, despite current tariff challenges [20][21] - The company is actively monitoring consumer sentiment and adapting its strategies to maintain market share amid a weak consumer environment [31][30] Other Important Information - The company is not planning any buybacks for the year but remains open to capital allocation opportunities depending on how the year unfolds [99] - The company is investing in innovation and marketing to ensure long-term growth, particularly in the chocolate category [113][114] Q&A Session Summary Question: What is the risk of tariff expenses in Q3 and Q4? - Management indicated that unmitigated tariff impacts could reach up to $100 million per quarter, primarily from cocoa and Canadian retaliatory tariffs [8][9] Question: How should investors think about the magnitude of EPS decline in Q2? - Management expects EPS to be down about 30% for the first half, with Q2 showing a decline less than Q1 due to strong net sales [12][14] Question: What is the outlook for earnings growth next year? - Management maintains a positive outlook for earnings growth next year, despite the challenges posed by tariffs [20][21] Question: How is the company addressing consumer trends towards healthier eating? - Management noted that while consumer sentiment is weak, the chocolate category remains resilient, and they are focusing on premium and permissible products [31][30] Question: What is the competitive landscape in the U.S. chocolate market? - Management reported no significant changes in the competitive landscape, with smaller players softening and larger players increasing innovation [124] Question: How will the company approach pricing in light of cocoa prices? - Management confirmed that pricing will increase in Q2 and Q3 as part of their seasonal pricing strategy [128]

Financial Data and Key Metrics Changes - The company reported operating earnings growth of 21% and EPS growth of 13%, with EPS for the quarter at $2.35 [11][12] - Total company revenue was flat at nearly $55 billion, but adjusted for contract expiration, revenue increased by 19% year-over-year [12][21] - Total company gross profit dollars increased by 10%, while SG&A increased by only 4%, indicating strong cost control [12][13] Business Line Data and Key Metrics Changes - Pharmaceutical and Specialty Solutions revenue was relatively flat at $50.4 billion, but excluding customer contract expiration, revenue increased by 20% [14][15] - GNPD segment revenue increased by 2% to $3.2 billion, driven by volume growth from existing customers [16] - Other businesses reported a 13% revenue increase to $1.3 billion, with At Home Solutions growing by 12%, Optifreight Logistics by 17%, and Nuclear by 14% [18] Market Data and Key Metrics Changes - The company generated over 99% of its enterprise revenue in the U.S., with 95% of segment profit from four of its five businesses largely unaffected by tariffs [6][7] - The company expects fiscal year 2025 revenue growth of 17% to 19% and segment profit growth of 16% to 18% in its Other segment [24] Company Strategy and Development Direction - The company has invested approximately $7 billion in the U.S. over the last two years, focusing on acquisitions, domestic manufacturing, and technology [7] - The company aims to enhance patient access, affordability, and innovation in healthcare while navigating regulatory complexities [6][7] - The addition of Advanced Diabetes Supply Group is expected to be accretive to EPS and enhance the company's capabilities in diabetes care [10][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to generate sustainable long-term growth and raised fiscal year 2025 EPS guidance to a range of $8.5 to $8.15 [10][21] - The company anticipates continued strong demand and organic growth driven by favorable market trends and competitive positioning [27][29] - Management acknowledged potential challenges from tariffs but emphasized proactive measures to mitigate impacts on customers and operations [35][36] Other Important Information - The company completed the acquisition of GI Alliance and Integrated Oncology Network, which are performing as expected [9][10] - The company has delivered adjusted free cash flow of $1.2 billion year-to-date and repurchased $750 million in shares [19][20] Q&A Session Summary Question: Strong brand and specialty sales growth - Management noted broad-based strength in brand and specialty sales, driven by multiple categories and new customer onboarding [44][46] Question: Consumer weakness related to tariffs - Management indicated no significant changes in consumer behavior or prescription demand despite macroeconomic concerns [53][54] Question: Cardinal Health brand revenue and USMCA coverage - Approximately $4 billion of GNPD revenue comes from Cardinal Health brand, which is higher margin relative to national brands [59][60] Question: Tariff impact on Cardinal Health brand - The majority of the anticipated $200 to $300 million in tariff costs will be addressed through pricing adjustments, particularly for Cardinal Health brand products [64][66] Question: Margin expansion in pharma - Management attributed margin expansion to growth in specialty and brand drug sales, acquisitions, and effective cost control measures [84][86] Question: Customer onboarding and new customer wins - The onboarding of new customers is progressing well, with a reaffirmation of $10 billion in incremental new customer revenue for the year [95][96]

Financial Data and Key Metrics Changes - Teleflex reported Q1 2025 revenues of $700.7 million, a 5% decrease year over year on a GAAP basis, and a decline of 3.8% on an adjusted constant currency basis, which was within the guidance range of -3% to -4% [6][24] - Adjusted earnings per share (EPS) for the first quarter was $2.91, reflecting a 9.3% decrease year over year [6][24] - Adjusted gross margin was 60.4%, a 70 basis point decrease compared to the prior year, primarily due to cost inflation and unfavorable product mix [22] - Adjusted operating margin was 24.7%, a 190 basis point decline year over year [22] Business Line Data and Key Metrics Changes - **Americas**: Revenues were $475.7 million, a 3.2% decrease year over year, impacted by OEM declines and challenges in the UroLift service [7] - **EMEA**: Revenues decreased 2.8% year over year to $151.2 million, with strong performance in Surgical and Vascular Access offset by anesthesia [8] - **Asia**: Revenues were $73.8 million, a 9.7% decrease year over year, in line with expectations due to volume-based procurement impacts [8] - **Vascular Access**: Revenue increased 1.9% year over year to $182.4 million, driven by growth in PICCs [9] - **Interventional**: Revenue was $137.5 million, an increase of 3.2% year over year, led by strong demand for intra-aortic balloon pumps [10] - **Anesthesia**: Revenue decreased 8.6% year over year to $86.6 million, with growth in endotracheal tubes offset by declines in military orders [11] - **Surgical**: Revenue increased 2% year over year to $105.8 million, with solid underlying trends [11] - **Interventional Urology**: Revenue decreased 10.7% year over year to $71 million, with strong growth in BarriGel but pressure on UroLift [12] - **OEM**: Revenue decreased 26.8% year over year to $63.9 million, impacted by a lost customer contract [12] Market Data and Key Metrics Changes - The company experienced softness in orders in EMEA during Q1, which has since recovered in April [6] - The China business is expected to see sequential quarterly revenue improvement through the remainder of 2025 [9] Company Strategy and Development Direction - Teleflex announced plans to separate into two independent publicly traded companies to enhance shareholder value, with significant inbound interest in acquiring NewCo [17][18] - The acquisition of BioTronix Vascular Intervention business is on track to close by the end of Q3 2025, expected to enhance Teleflex's portfolio in the cath lab [19][20] Management's Comments on Operating Environment and Future Outlook - Management noted that the first quarter evolved largely as expected, with specific headwinds anticipated to be transitory [33] - The company expects 2025 adjusted constant currency revenue growth of 1% to 2%, with an updated guidance range for reported revenue growth [26] - Tariffs are expected to impact 2025 results, with an estimated $55 million headwind, primarily associated with China and Mexico [28][29] Other Important Information - The company is actively exploring strategies to mitigate tariff exposure, including optimizing the supply chain and increasing the mix of USMCA compliant products [29][30] - The company has implemented thoughtful spending controls to offset tariff impacts [53] Q&A Session Summary Question: Has there been any incremental demand on the OEM side due to supply chain issues? - Management noted a pickup in demand within the OEM business, indicating base demand rather than supply chain issues [41] Question: Can you provide more details on the $55 million tariff impact and mitigation strategies? - Management explained that the $55 million is based on current tariffs and does not include mitigation strategies, which are being explored [46][52] Question: What is the interest level in NewCo, and is there a preference for a sale versus a spin? - Management indicated significant interest in NewCo, with a parallel process for both spin and sale being pursued [59][64] Question: How does the tariff impact split between RemainCo and SpinCo? - Management stated that the impact of tariffs will affect both entities, but specifics will be discussed closer to the separation date [81] Question: What are the early views on cost and revenue synergies from the BioTronix acquisition? - Management highlighted the opportunity to leverage BioTronix's channel in Europe and Teleflex's channel in the Americas for revenue growth [84]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $133.4 million, a 4% increase compared to Q1 2024, driven by favorable product mix and higher volumes, partially offset by average price decreases and foreign currency impacts [20] - Gross profit was $32.8 million, with a gross profit margin of 24.6%, up from 23.4% in the previous year [21] - Operating profit improved to $2.3 million from an operating loss of $943,000 in Q1 2024 [22] - Net income was $1.8 million or $0.13 per diluted share, compared to a net loss of $1.2 million or $0.08 per diluted share a year ago [23] - Net cash provided by operating activities was $6.6 million, down from $19.7 million in Q1 2024 [24] Business Line Data and Key Metrics Changes - Hamilton Beach brand sales saw modest growth, primarily from the U.S. Consumer and Latin America businesses [8] - The premium business delivered mid-single-digit growth, driven by new product launches, particularly in the Nu Milk and Qi brands [9] - The Health Beacon business contributed $1.5 million in revenue, marking its third consecutive quarter of increasing patient subscriptions [12] Market Data and Key Metrics Changes - North American consumer markets showed solid growth, with the U.S. market being the primary contributor [20] - International revenue experienced slight declines, indicating challenges in overseas markets [20] Company Strategy and Development Direction - The company is focused on six strategic initiatives: driving core growth, gaining share in the premium market, leading in the global commercial market, accelerating growth of Hamilton Beach Health, enhancing digital transformation, and leveraging partnerships and acquisitions [7] - The launch of the new premium brand Lotus is expected to capture share in the $4 billion total addressable premium market [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged increasing macroeconomic headwinds and the challenges posed by tariffs, but expressed confidence in navigating these issues [6] - The company plans to suspend guidance temporarily due to the unpredictability of trade negotiations and their potential impacts [26] Other Important Information - The company has transitioned approximately 15% of its manufacturing out of China and aims for two-thirds of U.S. sales to come from outside China by the end of 2025 [16] - The company is taking proactive measures to mitigate tariff impacts, including price increases and sourcing diversification [15] Q&A Session Summary Question: Clarification on gross margin outlook with tariffs - Management indicated that while they are working to mitigate tariff impacts, they do not have clear visibility on gross margins going forward [30] Question: Cost comparison of sourcing outside China - Management stated that they believe they can maintain margins despite potential cost variations when diversifying production outside of China [34][37] Question: Retailers' response to price increases - Management noted that there is open communication with retailers regarding price increases, and both parties are navigating the situation together [42] Question: Performance breakout for HealthBeacon - Management confirmed that HealthBeacon's performance will continue to be reported in segment disclosures and is growing at a better-than-expected rate [46]